Thalia Therapeutics (LSE:THAT) FCF Margin %: -17,925.00% (As of Dec. 2025)


What is Thalia Therapeutics FCF Margin %?

Thalia Therapeutics LSE:THAT -3.70% FCF Margin % is -17,925.00% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, Thalia Therapeutics ranks worse than 94.58% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Thalia Therapeutics's Free Cash Flow for the six months ended in Dec. 2025 was £-0.72 Mil. Thalia Therapeutics's Revenue for the six months ended in Dec. 2025 was £0.00 Mil. Therefore, Thalia Therapeutics's FCF Margin % for the quarter that ended in Dec. 2025 was -17,925.00%.

As of today, Thalia Therapeutics's current FCF Yield % is -18.95%.

The historical rank and industry rank for Thalia Therapeutics's FCF Margin % or its related term are showing as below:

LSE:THAT' s FCF Margin % Range Over the Past 10 Years
Min: -60450   Med: -13885.71   Max: -32.55
Current: -14512.5

During the past 13 years, the highest FCF Margin % of Thalia Therapeutics was -32.55%. The lowest was -60450.00%. And the median was -13885.71%.

LSE:THAT's FCF Margin % is ranked worse than
94.58% of 960 companies
in the Biotechnology industry
Industry Median: -85.21 vs LSE:THAT: -14512.50

Thalia Therapeutics FCF Margin % Related Terms

Thalia Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Thalia Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thalia Therapeutics FCF Margin % Chart

Thalia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -60,450.00 -13,885.71 -16,585.71

Thalia Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29,050.00 -9,775.00 -19,366.67 -11,100.00 -17,925.00

LSE:THAT vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Thalia Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thalia Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thalia Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Thalia Therapeutics's FCF Margin % falls into.


Thalia Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Thalia Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1.161/0.007
=-16,585.71 %

Thalia Therapeutics's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.717/0.004
=-17,925.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -17,925.00% mean?
Thalia Therapeutics (LSE:THAT) has a FCF Margin % of -17,925.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Thalia Therapeutics and its competitors. According to the industry distribution chart, Thalia Therapeutics ranks #908 out of 960 companies in the Biotechnology industry, placing it in the top 94.6%.
Is Thalia Therapeutics' FCF Margin % too high?
Thalia Therapeutics' current FCF Margin % is -17,925.00%. Based on the distribution chart, Thalia Therapeutics ranks #908 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Thalia Therapeutics' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thalia Therapeutics ranks #908 out of 960 companies for FCF Margin %. This places Thalia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Thalia Therapeutics and its competitors. Thalia Therapeutics's current FCF Margin % is -17,925.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thalia Therapeutics stock overvalued right now?
Thalia Therapeutics (LSE:THAT) has a current FCF Margin % of -17,925.00%. The current FCF Margin % is -17,925.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Thalia Therapeutics (LSE:THAT), the current FCF Margin % is -17,925.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thalia Therapeutics Business Description

Other Exchanges 0GO:Germany
Address 2 Portman Street, London, GBR, W1H 6DU
Thalia Therapeutics PLC is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. Its pipeline includes a long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein(a) [Lp(a)], which are established risk factors for cardiovascular disease.